✦ LIBER ✦

9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC

✍ Scribed by Brugger, W.; Kim, J.-H.; Hansen, O.; Sulllivan, R.; White, S.; Lee, J.-S.; Schlegel, M.; Noe, J.; Nagelmeier, I.; Cappuzzo, F.

Book ID: 123100431
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71889-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

22LBA Overall survival analyses from the

22LBA Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC)

✍ F. Cappuzzo; B. Coudert; R. Wierzbicki; K. Park; F. Custers; G.A. Curbera; G. Gi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

9158 A phase III study of erlotinib as m

9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)

✍ Cappuzzo, F.; Coudert, B.; Wierzbicki, R.; Park, K.; Custers, F.; Curbera, G.A.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Randomized, Placebo-Controlled, Phase II

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer

✍ Mok, T. S.K.; Wu, Y.-L.; Yu, C.-J.; Zhou, C.; Chen, Y.-M.; Zhang, L.; Ignacio, J 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 151 KB

Bevacizumab in Combination With Chemothe

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

✍ Ohtsu, A.; Shah, M. A.; Van Cutsem, E.; Rha, S. Y.; Sawaki, A.; Park, S. R.; Lim 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

Biomarker Analyses from a Placebo-Contro

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

✍ Koeppen, H.; Yu, W.; Zha, J.; Pandita, A.; Penuel, E.; Rangell, L.; Raja, R.; Mo 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 677 KB

9101 POSTER Pre-planned Subgroup Analyse

9101 POSTER Pre-planned Subgroup Analyses From the Phase III, Randomised, Placebo-controlled, Parallel-group Study of Gefitinib (G) as Maintenance Therapy in Patients (pts) With Locally Advanced or Metastatic Non-small-cell Lung Cancer (NSCLC) (INFORM; C-TONG 0804)

✍ Zhang, L.; Ma, S.L.; Song, X.Q.; Cheng, Y.; Huang, C.; Yang, S.J.; Liu, X.Q.; Li 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB